Unveiling Smart Investment Strategies for Lantheus (LNTH)

By Kim Brooks • Wednesday, November 20 15:17 • Permanent Link

Lantheus logged a 7.8% change during today's afternoon session, and is now trading at a price of $85.67 per share. The S&P 500 index moved -0.0%. LNTH's trading volume is 1,430,997 compared to the stock's average volume of 881,195.

Lantheus trades -36.07% away from its average analyst target price of $134.0 per share. The 11 analysts following the stock have set target prices ranging from $110.0 to $166.0, and on average have given Lantheus a rating of buy.

If you are considering an investment in LNTH, you'll want to know the following:

Lantheus's current price is 145.7% above its Graham number of $34.86, which implies that at its current valuation it does not offer a margin of safety
Lantheus has moved 11.6% over the last year, and the S&P 500 logged a change of 29.9%
Based on its trailing earnings per share of 6.02, Lantheus has a trailing 12 month Price to Earnings (P/E) ratio of 14.2 while the S&P 500 average is 29.3
LNTH has a forward P/E ratio of 12.4 based on its forward 12 month price to earnings (EPS) of $6.93 per share
Its Price to Book (P/B) ratio is 5.05 compared to its sector average of 3.53
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
Based in Bedford, the company has 834 full time employees and a market cap of $5.96 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.